faropenem medoxomil

a faropenem prodrug for treating bacterial infections
Also Known As:
A0026; BAY 56-6854; BAY 566854; BAY-56-6854; BAY-566854; BAY56-6854; BAY566854; SUN 208; SUN A0026; SUN-208; SUN-A0026; SUN208; faropenem daloxate
Networked: 7 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Tosiello, Robert: 2 articles (12/2006 - 10/2006)
2. Bassett, Jennifer: 1 article (05/2010)
3. Beaudry, Amber: 1 article (05/2010)
4. Miller, Lynda: 1 article (05/2010)
5. Gill, Stanley C: 1 article (05/2010)
6. Janjic, Nebojsa: 1 article (05/2010)
7. Heine, Henry S: 1 article (05/2010)
8. Critchley, Ian: 1 article (05/2010)
9. Rubino, Christopher M: 1 article (05/2010)
10. Stone, Kimberly Clawson: 1 article (05/2010)

Related Diseases

1. Community-Acquired Infections
2. Sinusitis
10/01/2006 - "To compare the efficacy and safety of faropenem medoxomil, 300 mg twice daily for seven or ten days, with cefuroxime axetil 250 mg twice daily for ten days in adults with acute bacterial sinusitis (ABS). "
10/01/2006 - "Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis."
04/01/2003 - "In this multicentre, multinational, comparative, double-blind clinical trial, outpatients with both clinical signs and symptoms and radiographic evidence of acute sinusitis were randomly assigned to receive for 7 days either a twice-daily oral regimen of faropenem daloxate (300 mg) or a twice daily oral regimen of cefuroxime axetil (250 mg). "
01/01/2008 - "Replidyne is developing faropenem medoxomil, the ester-type prodrug of faropenem, for the treatment of bacterial infections and respiratory tract infections, including acute exacerbations of chronic bronchitis (AECB), acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP). "
04/01/2007 - "Prospective, multicenter, randomized, double-blind, comparative (not vs placebo) clinical trials of acute bacterial sinusitis (ABS), acute exacerbations of chronic bronchitis (AECB), community-acquired pneumonia (CAP) and uncomplicated skin and skin structure infections (uSSSIs) have demonstrated that faropenem medoxomil has equivalent efficacy and safety compared with cefuroxime, clarithromycin, azithromycin, amoxicillin, cefpodoxime and amoxicillin-clavulanate. "
3. Chronic Bronchitis
4. Pneumonia (Pneumonitis)
5. Infection

Related Drugs and Biologics

1. Clavulanic Acid (Potassium Clavulanate)
2. Azithromycin (Zithromax)
3. Clarithromycin (Biaxin)
4. Cefuroxime (Zinacef)
5. Amoxicillin (Wymox)
6. cefpodoxime
7. fropenem (faropenem)
8. cefuroxime axetil (Ceftin)
9. Simvastatin (Zocor)
10. Daptomycin

Related Therapies and Procedures

1. Stents